Healthcare Analyst Schimmer, along with Drs. Scarupa and Spergel discuss ARS Pharmaceuticals (SPRY)’ Neffy (epinephrine nasal spray), on an Analyst/Industry conference call to be held on October 31 at 2 pm. Webcast Link
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on SPRY:
- ARS Pharmaceuticals showcases intranasal epinephrine data at ACAAI meeting
- ARS Pharmaceuticals announces U.S. availability of neffy
- ARS Pharmaceuticals submits sNDA to FDA for neffy 1 mg
- ARS Pharmaceuticals launches pre-ordering services for neffy
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
